<DOC>
	<DOCNO>NCT00520650</DOCNO>
	<brief_summary>This post-market surveillance , treatment patient depend upon decision base physician 's clinical judgment . The health profile switch period , 12 week short-term use , 52 week long-term use aripiprazole record evaluate .</brief_summary>
	<brief_title>Health Evaluation Abilify Long-term Therapy</brief_title>
	<detailed_description>Further study detail provide Taiwan Otsuka Pharmaceutical Co. , Ltd .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1 . Male female patient age 18 65 . 2 . Having DSMIV diagnosis schizophrenia schizoaffective disorder . 3. Who currently take antipsychotic drug clinically intolerable inadequately control base upon clinical judgment investigator . 1 . Pregnant breast feed woman plan pregnancy . 2 . Patient receive electroconvulsive therapy within 4 week Screening Visit . 3 . A know allergy reaction antipsychotic medication ( include limit haloperidol , chlorpromazine , thioridazine , pimozide , risperidone , quetiapine , ziprasidone ) . 4 . Patient clinically relevant organic , neurological , cardiovascular disease . 5 . Patient history drug alcohol abuse within last 12 week . 6 . Acute psychosis , acute suicidal ideation , acute psychiatric condition might require emergent intervention . 7 . Any clinical condition significant concurrent disease judge investigator complicate evaluation study treatment . 8 . Having participated investigational drug study take investigation drug within one month prior study entry . 9 . Depot neuroleptic discontinue least 2 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>